15 results
424B3
ADAP
Adaptimmune Therapeutics Plc
20 Apr 23
Prospectus supplement
4:32pm
with the SEC and other filing fees incident to the Form S-4 and the joint proxy statement/prospectus and the costs and expenses associated with printing
S-4/A
ADAP
Adaptimmune Therapeutics Plc
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
with the SEC and other filing fees incident to the Form S-4 and the joint proxy statement/prospectus and the costs and expenses associated with printing
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
to time, including, to the extent applicable, European Data Protection Laws.
(nn)
“Data Security Incident” is defined in Section 10.7 (Data Incident … surviving right under this Agreement.
Data Incident. When transferring Confidential Information pursuant to this Agreement, all communications
S-4
ADAP
Adaptimmune Therapeutics Plc
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
, Adaptimmune and TCR2 have agreed to share equally all costs and expenses incurred in connection with the SEC and other filing fees incident to the Form S
S-3ASR
EX-1.2
20l b8o6mzik
10 Aug 20
Automatic shelf registration
5:01pm
8-K
EX-1.1
rkhvzqrnjqo l5swgi4u
2 Jun 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
4:49pm
8-K
EX-1.1
9g2scuzoun9 mm7
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm
DRS
nv2 p7xqkcu1
5 Feb 15
Draft registration statement
12:00am
DRS
EX-10.3
vsz4yw rfje6c0nmbj14
5 Feb 15
Draft registration statement
12:00am
DRS
EX-10.4
06fdv
5 Feb 15
Draft registration statement
12:00am
- Prev
- 1
- Next